Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Free Report)'s share price fell 1.9% during mid-day trading on Monday . The company traded as low as $56.22 and last traded at $56.91. 275,330 shares changed hands during trading, an increase of 45% from the average session volume of 189,291 shares. The stock had previously closed at $58.00.
Gemini Therapeutics Stock Down 2.5%
The company has a market cap of $2.44 billion, a PE ratio of -56.27 and a beta of -0.12. The stock's 50 day moving average is $50.50 and its 200-day moving average is $51.68.
Gemini Therapeutics Company Profile
(
Get Free Report)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
Before you consider Gemini Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gemini Therapeutics wasn't on the list.
While Gemini Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
